Bausch + Lomb raises 2026 guidance to $5.450B-$5.550B revenue and $1.090B-$1.140B adjusted EBITDA as Vision '27 momentum continues (NYSE:BLCO)

Bausch + Lomb (BLCO) raised its 2026 revenue guidance to $5.45B-$5.55B and adjusted EBITDA to $1.09B-$1.14B, citing continued momentum from its Vision '27 strategy. The company reported its fourth consecutive quarter of meeting Investor Day commitments, according to Interim CEO Thomas.

Original reporting
Published Oct 28, 2026, 5:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 5:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BLCO
Bullish
high confidence
Mentioned
$BLCO
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$BLCOBullishMed
01

Why it matters

The guidance raise is a primary disclosure with material scale, likely prompting a positive price reaction.

02

Market read

Guidance lift is a significant catalyst for BLCO and may influence related ophthalmic stocks.

03

What to watch

Potential supply‑chain constraints or regulatory hurdles could temper growth.

Relevance 9/10Novelty 8/10Timing: pre‑market today

Background

Bausch + Lomb (NYSE:BLCO) announced an upward revision to its 2026 revenue and EBITDA guidance during its Q3 earnings call.

Company-level read

Ticker impact

$BLCOBullishHigh confidence
Context

Company raised 2026 revenue guidance to $5.45B-$5.55B and adjusted EBITDA to $1.09B-$1.14B.

Expected impact

potential upside as market prices in higher revenue outlook

Evidence & confidence

Guidance increase of several hundred million dollars is material and new, prompting traders to consider buying on the news.

Market effects

Positive outlook may lift other vision‑care and ophthalmic device peers.

U.S. healthcare sector could see modest gains.

Limited to companies with exposure to eye‑care market.

Counterpoint

If guidance already priced in, the stock may face a short‑term pull‑back.

Key entities

  • Bausch + Lomb

    Vision care company listed on NYSE under ticker BLCO.

Related articles

$BLCOMedAI 8/10

Bausch + Lomb (BLCO) BL1332 Misses Phase 2 Primary Endpoint

Bausch + Lomb's (BLCO) Phase 2 study for BL1332 missed its primary endpoint, showing no statistically significant improvement over the vehicle. The LS mean differences were -11.5 and -9.0, favoring BL1332 but not reaching significance. A 0.30% dose showed nominal significance at six hours for a secondary endpoint, with adverse event rates reported but no serious events.

$BLCOMedAI 8/10

What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call

Bausch + Lomb (BLCO) reported Q3 earnings, highlighting growth across multiple franchises. Adjusted gross margin rose to 64.7%, with operating cash flow at $233M. The company raised its 2026 revenue outlook to $5.45B-$5.55B and adjusted EBITDA guidance to $1.09B-$1.14B. Interim CEO Appio focused on profitability and R&D pipeline advancements.

$BLCOHighAI 8/10

Bausch & Lomb Corp (BLCO) (Q3 2026) Earnings Call Highlights: Strong Revenue Growth

Bausch & Lomb Corp (BLCO) reported Q3 2026 revenue growth of 8%, with all segments showing gains. Adjusted EBITDA rose 34% to $325M. The company raised full-year revenue and EBITDA guidance. Key products like MIBO and Lumify saw strong growth, while surgical equipment revenue declined 11%. The company faces regulatory and competitive pressures. Leadership changes were announced, with Tom Appio becoming interim CEO.

$BLCOHighAI 8/10

Bausch + Lomb Soars 16% on Big Q3 Profit Beat and Raised Full-Year Guidance

Bausch + Lomb's shares rose 16% after Q3 earnings beat expectations, with adjusted EPS at $0.34 vs. $0.22 consensus and revenue up 7% to $1.375B. Adjusted EBITDA increased 34% to $325M, and the company raised its full-year EBITDA guidance by $65M. Key growth drivers included MIEBO, LUMIFY, and premium intraocular lenses. Johnson & Johnson's contact lens sales also grew, contrasting with Cooper Companies' flat sales.